Učitavanje...
Elotuzumab as a novel anti-myeloma immunotherapy
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...
Spremljeno u:
| Izdano u: | Hum Vaccin Immunother |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5557243/ https://ncbi.nlm.nih.gov/pubmed/28604269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1327487 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|